Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRP | O00591 | 20/20 | 0.66 |
| ▸ | GABRD | O14764 | 20/20 | 0.66 |
| ▸ | GABRA1 | P14867 | 20/20 | 0.66 |
| ▸ | GABRB1 | P18505 | 20/20 | 0.66 |
| ▸ | GABRG2 | P18507 | 20/20 | 0.66 |
| ▸ | GABRB3 | P28472 | 20/20 | 0.66 |
| ▸ | GABRA5 | P31644 | 20/20 | 0.66 |
| ▸ | GABRA3 | P34903 | 20/20 | 0.66 |
| ▸ | GABRA2 | P47869 | 20/20 | 0.66 |
| ▸ | GABRB2 | P47870 | 20/20 | 0.66 |
| ▸ | GABRA4 | P48169 | 20/20 | 0.66 |
| ▸ | GABRE | P78334 | 20/20 | 0.66 |
| ▸ | GABRA6 | Q16445 | 20/20 | 0.66 |
| ▸ | GABRG1 | Q8N1C3 | 20/20 | 0.66 |
| ▸ | GABRG3 | Q99928 | 20/20 | 0.66 |
| ▸ | GABRQ | Q9UN88 | 20/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7570800 | 0.92 | GABRP (0.64) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL7570822 | 0.86 | GABRP (0.53) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL6928213 | 0.79 | GABRP (1.00) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL6927865 | 0.77 | GABRP (1.00) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL7967758 | 0.76 | GABRP (0.78) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL6922947 | 0.76 | GABRP (1.00) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL6927512 | 0.75 | GABRP (1.00) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL6927164 | 0.75 | GABRP (1.00) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL6926663 | 0.74 | GABRP (1.00) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL6926890 | 0.74 | GABRP (1.00) | GABRPGABRDGABRA1GABRB1GABRG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6448265-B1 | CORTICOTROPIN RELEASING FACTOR(CRF); ANTIDEPRESSANT; (5-AMINO-1-(2,6-DICHLORO-4-TRIFLUOROMETHYLPHENYL)-3-METHYLSULFANYL-1H -PYRAZOL-4-YL)-(2,5-DIMETHYLPHENYL)METHANONE FOR EXAMPLE | PFIZER, INC. | 2002-09-10 | — | — | US | disclosed |
| US-6441018-B2 | TREATMENT OF A WIDE RANGE OF DISEASES INCLUDING STRESS-RELATED ILLNESSES. | PFIZER INC. | 2002-08-27 | — | — | US | disclosed |
| US-20020049227-A1 | PYRAZOLES AND PYRAZOLOPYRIMIDINES HAVING CRF ANTAGONISTIC ACTIVITY | FARACI WILLIAM STEPHAN (US) | 2002-04-25 | — | — | US | disclosed |
| US-20020016333-A1 | PYRAZOLES AND PYRAZOLOPYRIMIDINES HAVING CRF ANTAGONISTIC ACTIVITY | FARACI WILLIAM STEPHEN (US) | 2002-02-07 | — | — | US | disclosed |
| US-6103900-A | CORTICOTROPIN RELEASING FACTOR (CRF) ANTAGONIST WHICH TREAT STRESS-INDUCED DISEASES | PFIZER INC (US) | 2000-08-15 | — | — | US | disclosed |
| US-6005109-A | CORTICOTROPIN RELEASING FACTOR (CRF) ANTAGONIST ACTIVITY; EFFECTIVE IN THE TREATMENT OF A WIDE RANGE OF DISEASES INCLUDING STRESS-RELATED ILLNESSES | PFLIZER INC. (US) | 1999-12-21 | — | — | US | disclosed |
| US-5712303-A | ANTIDEPRESSANTS | PFIZER INC. (US) | 1998-01-27 | — | — | US | disclosed |
| EP-0674624-A1 | PYRAZOLES AND PYRAZOLOPYRIMIDINES HAVING CRF ANTAGONIST ACTIVITY | PFIZER INC. (US) | 1995-10-04 | — | — | EP | disclosed |
| WO-1994013643-A1 | PYRAZOLES AND PYRAZOLOPYRIMIDINES HAVING CRF ANTAGONIST ACTIVITY | PFIZER INC. (US) | 1994-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020016333-A1 | PYRAZOLES AND PYRAZOLOPYRIMIDINES HAVING CRF ANTAGONISTIC ACTIVITY | CRH, CRHR1, CRHR2 | GABRP 709/4885GABRD 1471/4885GABRA1 862/4885 |
| US-20020049227-A1 | PYRAZOLES AND PYRAZOLOPYRIMIDINES HAVING CRF ANTAGONISTIC ACTIVITY | CRH, CRHR1, CRHR2 | GABRP 709/4885GABRD 1471/4885GABRA1 862/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.